Related Experiment Video
Updated: Feb 26, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Implementation of a Nurse-driven Educational Program Improves Management of Sorafenib's Toxicities in Hepatocellular
Angélique Brunot1, Florence Le Roy, Samuel Le Sourd
1Author Affiliations: Medical Oncology, Centre Eugene Marquis (Drs Brunot, Le Sourd, Crouzet, Boucher, Laguerre, and Edeline and Mss M'Sadek and Duval); and Hepatology Unit, CHU Pontchaillou (Drs Le Roy and Guillygomarc'h), Rennes, France.
Background:
Sorafenib is the standard treatment of advanced hepatocellular carcinoma. Because of its unique toxicities, improving patients' tolerance merits close follow-up. Nurses can play a crucial role by leading a patient educational program (EP).
Objectives:
The aim of this study was to assess whether adding EP to usual care (UC) improves patient's care.
Methods:
Since 2011, oncologists referred patients treated by sorafenib to the EP led by clinical nurses. The EP included a visit before the first administration, weekly telephone calls, and a visit with the nurse before each oncologist consultation. We retrospectively compared patients in the EP with those in UC followed by an oncologist and patients included in a clinical trial.
Results:
Since 2005, 129 patients were treated with sorafenib for hepatocellular carcinoma: 31 in the EP (24%), 22 in a clinical trial (17%), and 76 with UC (59%). Seventy-one percent of the patients in the EP had toxicities identified during a telephone call, which prompted symptomatic measures in 65% of the patients, leading to treatment modification before the planned on-site visit in 29% of the patients. Educational program patients required fewer dose reductions (39% vs 61% for UC, P = .04), and median time to first dose reduction was shorter with EP than with UC (25 vs 45 days, P = .036).
Conclusions:
This study suggests a clinical benefit of EP related to improved toxicity management of sorafenib that resulted in fewer dose reductions.
Implications For Practice:
Patients treated with sorafenib may benefit from an EP. Different types of EP should be compared prospectively, focusing on patients' quality of life.
Related Concept Videos
01:16Kidney Transplant III: Nursing Management
01:27Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's...
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:18Chronic Kidney Disease IV: Nursing Management
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...